Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365558 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02365558 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 34 participants.
The verdict
NCT02365558, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of increased stomach pH on how much evacetrapib is found in the blood stream and how long the body takes to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. There are two parts to the study. Participation in both parts will be required. The study will last approximately 30 days, not including screening.
Interventions
- DRUG Omeprazole
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365558
The ClinicalTrials.gov registry entry for NCT02365558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omeprazole is the first listed.
NCT02365558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365558 about?
NCT02365558 is a clinical study titled "A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants". The purpose of this study is to evaluate the effect of increased stomach pH on how much evacetrapib is found in the blood stream and how long the body takes to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. There are two p...
What is the current status of trial NCT02365558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-01. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02365558?
The interventions under investigation include: Omeprazole (DRUG), Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT02365558?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.